Assembly Bio exercises Gilead profit-share option for HSV drug programme
Assembly Biosciences has exercised its option to co-share 40% of United States development costs and profits for its herpes simplex virus (HSV) helicase-primase inhibitor programme, developed in collaboration with Gilead Sciences. The decision, announced on 8 September 2026, follows Assembly Bio's review of Gilead's full development plan for the programme, which includes two candidates: GS-1179 and GS-5366.
Under the collaboration agreement, Gilead retains sole responsibility for clinical development and commercialisation of both compounds. Outside the US, Assembly Bio remains eligible for up to $280 million in regulatory and commercial milestones, plus tiered royalties on net sales ranging from the high single digits to low teens. Should either party exercise opt-out or conversion rights, the US profit-share arrangement could transition to a separate milestone and royalty structure worth up to $330 million.
The deal mechanics
By electing into the profit-share, Assembly Bio takes on meaningful financial exposure in exchange for a proportionate upside on the US market, which accounts for the majority of antiviral revenues globally. The structure is notable for its optionality: the right to revert to a pure milestone-and-royalty model gives Assembly Bio a degree of risk management if the programme's commercial trajectory disappoints. Chief executive Jason Okazaki described the decision as reflecting confidence in the clinical data generated so far and in Gilead's development strategy, saying the programme "is positioned to deliver on its significant potential for patients suffering from recurrent genital herpes."
On the near-term clinical timeline, GS-1179 is expected to enter a Phase 2 trial in patients with recurrent genital herpes before the end of 2026. Gilead is also evaluating the compound as part of a combination strategy with HIV pre-exposure prophylaxis (PrEP), a pairing that could substantially expand the addressable population if the data support it. Economics for any such combination approach would be allocated under the existing collaboration framework based on the relative contribution of each programme component.
Assembly Bio's cash position is supported by a $75 million collaboration extension payment due from Gilead in the fourth quarter of 2026, triggered by the third anniversary of the partnership. Including that payment, the company projects its cash runway extends into 2029.
Market context
The HSV treatment market has been dominated for decades by nucleoside analogue therapies such as acyclovir and valacyclovir, which suppress viral replication but do not eliminate latent infection. Helicase-primase inhibitors represent a mechanistically distinct class: they target an enzyme complex essential for HSV replication, raising the prospect of improved virological suppression, and potentially once-weekly oral dosing in the case of GS-1179. A once-weekly regimen would be a meaningful convenience improvement over the twice-daily standard of care for recurrent genital herpes.
Competitive interest in this space has grown alongside broader attention to viral latency and immune modulation. Amenalief (amenamevir), a helicase-primase inhibitor approved in Japan for herpes zoster, demonstrates that the class can reach the market, though no helicase-primase inhibitor has yet been approved in the US or Europe for genital HSV. Regulatory agencies have signalled interest in endpoints beyond lesion recurrence rates, including viral shedding, which could shape the Phase 2 design Gilead now controls.
The combination angle with PrEP is strategically significant. Gilead's Descovy and Truvada are among the most widely used PrEP regimens, meaning the company has both commercial infrastructure and clinical relationships that could facilitate a co-formulated or co-prescribed product. Investors will be watching for Phase 2 protocol details, the proposed primary endpoint, and any update on the combination dosing strategy as the trial initiation approaches.